In the evolving landscape of gene therapy for Duchenne muscular dystrophy (DMD), one issue is becoming increasingly clear: CK levels after Duchenne gene therapy are far more important than viral videos circulating online.
Families are being exposed to emotionally powerful, time-lapse videos that appear to show improvement after treatment. However, these visual narratives are often presented without accompanying biochemical data—particularly Creatine Kinase (CK), AST, and ALT levels, which are essential for evaluating both efficacy and safety.
This raises a critical question:
Why are we seeing videos instead of the biomarker data that should define treatment outcomes?
Table of Contents
The Problem: Viral Videos Are Replacing Clinical Evidence
The Rise of Anecdotal Evidence in DMD
Videos of children walking, climbing stairs, or standing unassisted after gene therapy are widely shared. While these moments may be genuine, they are not scientifically reliable indicators of treatment success.
They lack:
- Controlled conditions
- Standardized functional scoring
- Baseline comparisons
- Long-term follow-up
Most importantly, they lack CK levels needed to determine whether muscle damage has truly decreased after gene therapy for Duchenne muscular dystrophy, as well as data on normal dystrophin expression.
Learn More: What is Creatine Kinase (CK)?
Why This Is Dangerous
When anecdotal content replaces objective data:
- Families may develop unrealistic expectations
- Treatment decisions may be influenced by incomplete information
- Scientific rigor is undermined
This is not a communication issue—it is a data transparency problem.
CK Levels After Duchenne Gene Therapy: The Core Biomarker
What CK Levels Represent
Creatine Kinase (CK) is a critical enzyme released when muscle fibers are damaged. In DMD:
- CK levels are typically extremely elevated
- Persistent elevation reflects ongoing muscle degeneration
After gene therapy, CK levels should be closely monitored to determine whether:
- Muscle damage is decreasing
- The therapy is producing a biological effect
- The disease process is being modified
Why CK Data Must Be Public
Without access to CK levels after Duchenne gene therapy:
- Claims of improvement remain unverified
- Functional gains cannot be linked to biological change
- Clinicians and families cannot make informed decisions
CK is not optional—it is fundamental.
AST and ALT: Essential Safety and Muscle Biomarkers
Beyond Liver Function
AST (Aspartate Aminotransferase) and ALT (Alanine Aminotransferase) are often misunderstood as purely liver enzymes. In DMD, they also reflect muscle integrity.
After gene therapy:
- Elevated AST/ALT may indicate muscle breakdown or treatment-related toxicity
- Changes in these markers provide critical safety signals
The Transparency Gap
Despite their importance:
- AST and ALT data are not consistently disclosed
- Public reporting is often incomplete or delayed
- Families are left without a full safety profile
This lack of transparency is unacceptable in high-risk therapies.
Why Are CK Levels After Duchenne Gene Therapy Not Fully Disclosed?
The Accountability Problem
Pharmaceutical companies developing gene therapies operate in a highly competitive environment. However, this does not justify withholding essential biomarker data.
When companies:
- Highlight visual improvements
- Share selective outcomes
- Delay biomarker disclosure
They create information asymmetry that disadvantages patients and clinicians.
The Role of Regulators
Organizations such as the European Medicines Agency are responsible for ensuring safety and transparency. However, public access to:
- CK trends
- AST/ALT data
- Long-term outcomes
remains limited in many cases.
Regulatory oversight must evolve to prioritize real-time data transparency.
The Ethical Issue: Emotion vs. Evidence
Families sharing videos are not the root problem—they are responding to a lack of accessible data. However, when these videos dominate the narrative:
- They can unintentionally mislead others
- They shift focus away from measurable outcomes
- They create pressure within the patient community
The real issue is a system where:
- Data is scarce
- Emotion fills the gap
This imbalance must be corrected.
What Real Transparency Should Look Like
To restore trust and scientific integrity, the field must adopt a new standard:
1. Routine Disclosure of CK Levels After Duchenne Gene Therapy
- Baseline vs. post-treatment comparisons
- Longitudinal tracking (months/years)
- Clear interpretation of trends
2. Full Reporting of AST and ALT
- Safety monitoring
- Adverse event detection
- Contextual explanation
3. Public Access to Data
- Open registries
- Downloadable datasets
- Visual dashboards
4. Independent Validation
- Third-party analysis
- Academic collaboration
- Regulatory review
The Consequences of Continued Opacity
If CK levels after Duchenne gene therapy remain undisclosed:
- Trust in gene therapy will decline
- Families may make misinformed decisions
- Scientific progress will slow
Transparency is not just a scientific requirement—it is an ethical obligation.
Frequently Asked Questions (FAQ)
What is CK and why is it important in Duchenne gene therapy?
Creatine Kinase (CK) is an enzyme released into the bloodstream when muscle fibers are damaged. In Duchenne muscular dystrophy, CK levels are typically very high because muscles continuously break down.
After gene therapy, CK is important because:
• A decrease in CK may indicate reduced muscle damage
• Stable or rising CK may suggest ongoing disease activity
• CK trends help evaluate whether therapy is having a biological effect, not just a visible one
In short: CK provides objective biochemical evidence, which videos alone cannot offer.
Are improvement videos after gene therapy reliable evidence?
No—videos are not reliable scientific evidence.
While they may show real moments, they lack:
• Standardized testing conditions
• Baseline comparisons
• Long-term follow-up
• Objective measurement scales
A child appearing stronger in a video could be influenced by:
• Motivation or encouragement
• Selective recording or editing
• Natural day-to-day variation
For clinical evaluation, doctors rely on:
• Functional scales (e.g., NSAA)
• Biomarkers like CK, AST, ALT
• Controlled clinical trial data
Videos can illustrate—but they cannot validate treatment effectiveness.
Why should AST and ALT levels be reported after gene therapy?
AST (Aspartate Aminotransferase) and ALT (Alanine Aminotransferase) are enzymes that reflect both liver and muscle health.
They are critical after gene therapy because:
• Elevated levels may indicate liver stress or toxicity
• In DMD, they also reflect muscle breakdown
• Sudden spikes can signal safety concerns
Monitoring AST and ALT helps:
• Assess treatment safety
• Detect adverse effects early
• Understand how the body is responding beyond visible changes
Without AST and ALT data, safety evaluation is incomplete.
Why don’t pharmaceutical companies publicly share full biomarker data?
There is no single reason, but common factors include:
• Regulatory timelines (data released after review processes)
• Selective reporting strategies (highlighting positive outcomes first)
• Concerns about misinterpretation of raw data
• Competitive and commercial considerations
However, in high-risk treatments like gene therapy:
• Transparency should outweigh these concerns
• Patients and families need complete, not partial, information
Organizations like the European Medicines Agency are expected to ensure that safety and efficacy data—including biomarkers—are accessible and reliable.
What should families look for instead of videos when evaluating gene therapy?
Families should prioritize objective, clinically validated data, including:
• CK level trends before and after treatment
• AST and ALT values for safety monitoring
• Results from controlled clinical trials
• Functional assessments (e.g., NSAA scores)
• Long-term follow-up data (12–24 months or more)
Additionally, families should:
• Consult neuromuscular specialists
• Review data from trusted regulators like the European Medicines Agency
• Be cautious of conclusions based solely on social media
The key principle: decisions should be based on data, not isolated visual impressions.
Read More: Why Creatine Kinase (CK), AST, ALT, and Dystrophin Levels Should Be Disclosed
Final Thoughts
The future of gene therapy in Duchenne muscular dystrophy depends on one principle: evidence must come before narrative.
Companies developing therapies—including Solid Biosciences (SGT-003), REGENXBIO (RGX-202), Genethon (GNT0004), and Satellos (SAT-3247)—are expected to publicly disclose CK levels after Duchenne gene therapy, along with AST and ALT data, through official channels such as the European Medicines Agency.
The community does not need more videos.
It needs data that can be measured, verified, and trusted.
Until that standard is met, skepticism is not resistance—it is responsibility.
Stop relying on unnecessary and unscientific videos—focus on sharing the data for Duchenne muscular dystrophy.
Academic Sources and References
Bushby, K., Finkel, R., Birnkrant, D. J., et al. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. The Lancet Neurology, 9(1), 77–93. https://doi.org/10.1016/S1474-4422(09)70271-6
Bushby, K., Finkel, R., Birnkrant, D. J., et al. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. The Lancet Neurology, 9(2), 177–189. https://doi.org/10.1016/S1474-4422(09)70272-8
Birnkrant, D. J., Bushby, K., Bann, C. M., et al. (2018). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, neuromuscular, rehabilitation, endocrine, and gastrointestinal management. The Lancet Neurology, 17(3), 251–267. https://doi.org/10.1016/S1474-4422(18)30024-3
Birnkrant, D. J., Bushby, K., Bann, C. M., et al. (2018). Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. The Lancet Neurology, 17(4), 347–361. https://doi.org/10.1016/S1474-4422(18)30025-5
Mendell, J. R., Sahenk, Z., Lehman, K., et al. (2020). Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy. New England Journal of Medicine, 383(21), 2039–2047. https://doi.org/10.1056/NEJMoa2002295
Duan, D. (2018). Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Molecular Therapy, 26(10), 2337–2356. https://doi.org/10.1016/j.ymthe.2018.03.012
Hathout, Y., Brody, E., Clemens, P. R., et al. (2015). Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences (PNAS), 112(23), 7153–7158. https://doi.org/10.1073/pnas.1507719112
McDonald, C. M., et al. (2018). Serum biomarkers in Duchenne muscular dystrophy. Neurology, 90(21), e1839–e1848. https://doi.org/10.1212/WNL.0000000000005515
Brancaccio, P., Lippi, G., & Maffulli, N. (2007). Biochemical markers of muscular damage. Clinical Chemistry and Laboratory Medicine, 45(5), 603–611. https://doi.org/10.1515/CCLM.2007.115
Nathwani, R. A., Pais, S., Reynolds, T. B., & Kaplowitz, N. (2005). Serum alanine aminotransferase in skeletal muscle diseases. Hepatology, 41(2), 380–382. https://doi.org/10.1002/hep.20548
High, K. A., & Roncarolo, M. G. (2019). Gene therapy. New England Journal of Medicine, 381(5), 455–464. https://doi.org/10.1056/NEJMra1706910
Mendell, J. R., & Rodino-Klapac, L. R. (2020). Duchenne muscular dystrophy: CRISPR/Cas9 treatment. Cell Research, 30(6), 465–466. https://doi.org/10.1038/s41422-020-0317-7
European Medicines Agency (EMA). Gene therapy regulatory guidelines and assessment reports. Available at: https://www.ema.europa.eu
U.S. Food and Drug Administration (FDA). Human gene therapy guidance for industry. Available at: https://www.fda.gov
